Login to Your Account



Pharma: Other News To Note


Wednesday, May 30, 2012
• CSL Behring Ltd., of King of Prussia, Pa., said the FDA accepted for review its biologics license application for a human 4-factor prothrombin complex concentrate for the urgent reversal of vitamin K-antagonist therapy (i.e. warfarin) in patients with acute major bleeding.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription